Absence of MGMT promoter methylation in endometrial cancer

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 224-228

  Rimel, B J ^a   Huettner, Phyllis ^b   Powell, Matthew A ^a   Mutch, David G ^a   Goodfellow, Paul J ^a,b  

^a Division of Gynecologic Oncology   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endometrial neoplasms; Methylation; MGMT

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ALKYLATION; ARTICLE; CANCER CELL CULTURE; COHORT ANALYSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; RESTRICTION MAPPING; TISSUE SECTION;

DNA METHYLATION; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS, GENETIC;

EID: 57649086534     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.08.038     Document Type: Article

References (27)

1. Ogino S., Meyerhardt J.A., Kawasaki T., et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 450 (2007) 529-537
2. Rodriguez M.J., Acha A., Ruesga M.T., Rodriguez C., Rivera J.M., and Aguirre J.M. Loss of expression of DNA repair enzyme MGMT in oral leukoplakia and early oral squamous cell carcinoma. A prognostic tool?. Cancer Lett. 245 (2007) 263-268
3. Ishii T., Murakami J., Notohara K., et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut. 56 (2007) 13-19
4. Weaver K.D., Grossman S.A., and Herman J.G. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest. 24 (2006) 35-40
5. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343 (2000) 1350-1354
6. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352 (2005) 997-1003
7. De Vita V.T., Hellman S., and Rosenberg S. Chapter 14: Section 4 "alkylating agents". Cancer: principles and practice of oncology. 7th ed (2005), Lippincott Williams and Wilkins, Philadelphia 408-409
8. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
9. McMeekin D.S., Filiaci V.L., Thigpen J.T., Gallion H.H., Fleming G.F., and Rodgers W.H. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol. Oncol. 106 (2007) 16-22
10. Pectasides D., Pectasides E., and Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat. Rev. 33 (2007) 177-190
11. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59 (1999) 793-797
12. Furlan D., Carnevali I., Marcomini B., Cerutti R., Dainese E., Capella C., et al. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin. Cancer Res. 12 (2006) 3329-3336
13. Herfarth K.K., Brent T.P., Danam R.P., et al. A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol. Carcinog. 24 (1999) 90-98
14. Kim J.R., Lee S.R., Chung H.J., Kim S., Baek S.H., Kim J.H., et al. Identification of amyloid beta-peptide responsive genes by cDNA microarray technology: involvement of RTP801 in amyloid beta-peptide toxicity. Exp. Mol. Med. 35 (2003) 403-411
15. Jacinto F., and Esteller M. MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair (Amst). 6 (2007) 1155-1160
16. Rantanen V., Grenman S., Kurvinen K., Hietanen S., Raitanen M., and Syrjanen S. p53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines. Gynecol. Oncol. 71 (1998) 352-358
17. Xiong Y., Dowdy S.C., Gonzalez Bosquet J., et al. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol. Oncol. 99 (2005) 135-141
18. Whitcomb B.P., Mutch D.G., Herzog T.J., Rader J.S., Gibb R.K., and Goodfellow P.J. Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin. Cancer Res. 9 (2003) 2277-2287
19. Zighelboim I., Goodfellow P.J., Schmidt A.P., et al. Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers. Clin. Cancer Res. 13 (2007) 2882-2889
20. Rodriguez F.J., Thibodeau S.N., Jenkins R.B., et al. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl. Immunohistochem. Mol. Morphol. 16 (2008) 59-65
21. Sutton G.P., Blessing J.A., DeMars L.R., Moore D., Burke T.W., and Grendys E.C. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol. Oncol. 63 (1996) 25-27
22. Pawinski A., Tumolo S., Hoesel G., et al. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. Eur. J. Obstet. Gynecol. Reprod. Biol. 86 (1999) 179-183
23. O'Brien V., and Brown R. Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis 27 (2006) 682-692
24. Goodfellow P.J., Buttin B.M., Herzog T.J., et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5908-5913
25. Zighelboim I., Goodfellow P.J., Gao F., et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J. Clin. Oncol. 25 (2007) 2042-2048
26. Wagner L.M., McLendon R.E., Yoon K.J., Weiss B.D., Billups C.A., and Danks M.K. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin. Cancer Res. 13 (2007) 5418-5425
27. 6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol. Rep. 17 (2007) 1461-1467